Molecular imaging is being increasingly applied in the management of PCa patients in PSA relapse and innovative radiopharmaceuticals are being proposed in nuclear medicine scenarios to identify a low tumor burden disease with higher sensitivity at an earlier time. The gene discussed is KLK3; the disease is posterior cortical atrophy.